Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8765 |
High Similarity |
NPD7228 |
Approved |
0.8679 |
High Similarity |
NPD6234 |
Discontinued |
0.8599 |
High Similarity |
NPD37 |
Approved |
0.8553 |
High Similarity |
NPD4966 |
Approved |
0.8553 |
High Similarity |
NPD4965 |
Approved |
0.8553 |
High Similarity |
NPD4967 |
Phase 2 |
0.8462 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.8443 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.8289 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.8242 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.8225 |
Intermediate Similarity |
NPD7240 |
Approved |
0.8205 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.8194 |
Intermediate Similarity |
NPD6190 |
Approved |
0.8176 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.8121 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.8095 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.8012 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.8 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7965 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7961 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7953 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7941 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7895 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7866 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7845 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7815 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7778 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7772 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7771 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7771 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7716 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7712 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7709 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7697 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7665 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7661 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7661 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7661 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7647 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.763 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.761 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7605 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.76 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.759 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7562 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7562 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7548 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7548 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7548 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7544 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7543 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7516 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7515 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7515 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7514 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7514 |
Intermediate Similarity |
NPD8312 |
Approved |
0.75 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7485 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7453 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.744 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7418 |
Intermediate Similarity |
NPD7296 |
Approved |
0.7414 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7378 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7375 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7375 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7372 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.7371 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7365 |
Intermediate Similarity |
NPD7028 |
Phase 2 |
0.7342 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7341 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7337 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7337 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7337 |
Intermediate Similarity |
NPD2801 |
Approved |
0.733 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7329 |
Intermediate Similarity |
NPD5958 |
Discontinued |
0.7325 |
Intermediate Similarity |
NPD7966 |
Clinical (unspecified phase) |
0.7315 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7303 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7302 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7294 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7293 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.729 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7256 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.725 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7239 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7237 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7226 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7226 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7225 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7222 |
Intermediate Similarity |
NPD4534 |
Discontinued |
0.7215 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7215 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7205 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.7197 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7197 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7176 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7171 |
Intermediate Similarity |
NPD1091 |
Approved |
0.717 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.716 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.716 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.716 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.716 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.716 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.716 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7135 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7135 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7134 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7126 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7118 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7101 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7083 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7081 |
Intermediate Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.7077 |
Intermediate Similarity |
NPD7874 |
Approved |
0.7077 |
Intermediate Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.7053 |
Intermediate Similarity |
NPD6778 |
Approved |
0.7053 |
Intermediate Similarity |
NPD6779 |
Approved |
0.7053 |
Intermediate Similarity |
NPD6780 |
Approved |
0.7053 |
Intermediate Similarity |
NPD6781 |
Approved |
0.7053 |
Intermediate Similarity |
NPD6782 |
Approved |
0.7053 |
Intermediate Similarity |
NPD6776 |
Approved |
0.7053 |
Intermediate Similarity |
NPD6777 |
Approved |
0.7051 |
Intermediate Similarity |
NPD5647 |
Approved |
0.7045 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7039 |
Intermediate Similarity |
NPD17 |
Approved |
0.7035 |
Intermediate Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.7035 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7032 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7018 |
Intermediate Similarity |
NPD6385 |
Approved |
0.7018 |
Intermediate Similarity |
NPD6386 |
Approved |
0.7016 |
Intermediate Similarity |
NPD2493 |
Approved |
0.7016 |
Intermediate Similarity |
NPD2494 |
Approved |
0.7011 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7007 |
Intermediate Similarity |
NPD228 |
Approved |
0.7006 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7006 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7006 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7 |
Intermediate Similarity |
NPD2979 |
Phase 3 |
0.6995 |
Remote Similarity |
NPD8319 |
Approved |
0.6995 |
Remote Similarity |
NPD4583 |
Approved |
0.6995 |
Remote Similarity |
NPD4582 |
Approved |
0.6995 |
Remote Similarity |
NPD8320 |
Phase 1 |
0.6994 |
Remote Similarity |
NPD6100 |
Approved |
0.6994 |
Remote Similarity |
NPD2935 |
Discontinued |
0.6994 |
Remote Similarity |
NPD6099 |
Approved |
0.6987 |
Remote Similarity |
NPD2797 |
Approved |
0.6964 |
Remote Similarity |
NPD3688 |
Clinical (unspecified phase) |
0.6964 |
Remote Similarity |
NPD5401 |
Approved |
0.6964 |
Remote Similarity |
NPD3146 |
Approved |
0.6962 |
Remote Similarity |
NPD4908 |
Phase 1 |
0.6959 |
Remote Similarity |
NPD6599 |
Discontinued |
0.6959 |
Remote Similarity |
NPD7999 |
Approved |
0.6957 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6957 |
Remote Similarity |
NPD1933 |
Approved |
0.6943 |
Remote Similarity |
NPD7698 |
Approved |
0.6943 |
Remote Similarity |
NPD7696 |
Phase 3 |
0.6943 |
Remote Similarity |
NPD4002 |
Approved |
0.6943 |
Remote Similarity |
NPD4004 |
Approved |
0.6943 |
Remote Similarity |
NPD7697 |
Approved |
0.6937 |
Remote Similarity |
NPD6663 |
Approved |
0.6935 |
Remote Similarity |
NPD7930 |
Approved |
0.6928 |
Remote Similarity |
NPD5125 |
Phase 3 |
0.6928 |
Remote Similarity |
NPD5126 |
Approved |
0.6927 |
Remote Similarity |
NPD3452 |
Approved |
0.6927 |
Remote Similarity |
NPD3450 |
Approved |
0.6923 |
Remote Similarity |
NPD6273 |
Approved |
0.6919 |
Remote Similarity |
NPD7827 |
Phase 1 |
0.6914 |
Remote Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.6912 |
Remote Similarity |
NPD5619 |
Clinical (unspecified phase) |
0.6907 |
Remote Similarity |
NPD7871 |
Phase 2 |
0.6907 |
Remote Similarity |
NPD7870 |
Phase 2 |
0.6899 |
Remote Similarity |
NPD5736 |
Approved |
0.6898 |
Remote Similarity |
NPD2490 |
Approved |
0.6898 |
Remote Similarity |
NPD2488 |
Approved |
0.6897 |
Remote Similarity |
NPD5353 |
Approved |
0.6897 |
Remote Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.6894 |
Remote Similarity |
NPD4140 |
Approved |
0.6891 |
Remote Similarity |
NPD6823 |
Phase 2 |
0.6888 |
Remote Similarity |
NPD7701 |
Phase 2 |
0.6875 |
Remote Similarity |
NPD919 |
Approved |
0.6875 |
Remote Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD3268 |
Approved |
0.6871 |
Remote Similarity |
NPD3021 |
Approved |
0.6871 |
Remote Similarity |
NPD3022 |
Approved |
0.6869 |
Remote Similarity |
NPD7801 |
Approved |
0.6869 |
Remote Similarity |
NPD7783 |
Phase 2 |
0.6869 |
Remote Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.6867 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6867 |
Remote Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.6864 |
Remote Similarity |
NPD2533 |
Approved |
0.6864 |
Remote Similarity |
NPD8389 |
Clinical (unspecified phase) |
0.6864 |
Remote Similarity |
NPD2534 |
Approved |
0.6864 |
Remote Similarity |
NPD2532 |
Approved |
0.6864 |
Remote Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.6863 |
Remote Similarity |
NPD5585 |
Approved |
0.6859 |
Remote Similarity |
NPD4420 |
Approved |
0.6853 |
Remote Similarity |
NPD8151 |
Discontinued |
0.6852 |
Remote Similarity |
NPD447 |
Suspended |
0.6848
|
Remote Similarity |
NPD1375 |
Discontinued |